The Asia Pacific Chlamydia trachomatis/Neisseria gonorrhoeae (CTNG) Testing Market should witness market growth of 9.2% CAGR during the forecast period (2023-2030).
Early Chlamydia and Gonorrhoeae detection becomes feasible by CT/NG testing, allowing rapid treatment and stopping the spread of diseases. As a result, communities see lower transmission rates, and individuals experience better health outcomes. The accuracy and specificity of CT/NG tests have also been improved due to developments in molecular diagnostics and genotyping techniques. These technologies make it possible to identify individual strains and patterns of medication resistance, enabling more precise treatment methods and improved infection control.
Personalized options for treatment are rendered accessible by incorporating genotyping and molecular diagnostics into CT/NG testing. It helps optimize treatment plans based on unique infection profiles, prevent antibiotic resistance, and enhance therapeutic outcomes. Additionally, the healthcare sector's integration of telemedicine and digital health platforms makes remote testing, consultations, and result distribution possible. In particular, for people in underprivileged areas, this removes geographic restrictions and improves accessibility to testing services. Professional people looking for testing services and telemedicine solutions in the market offer ease and privacy. Confidentiality is ensured with remote testing, removing obstacles and stigma connected to conventional in-person appointments.
According to a 2023 National Library of Medicine, publication named Sexually Transmitted Infections Among Key Populations in India: A Protocol for Systematic Review, between 0 to 3.9 percent of the general population in India has one of the four treatable STIs. However, subpopulations engaging in high-risk behavior are believed to have considerably greater STI prevalence than the general population. As a result, officials are taking more action to address the issues. The National AIDS Control Organization (NACO) has made STI prevention one of its primary goals in India for the past 20 years. Through its network of more than 1100 designated clinics, known as Suraksha Clinics, the NACO offers free sexual and reproductive health services based on syndromic case management through trained counselors, skilled paramedics, and experienced medical personnel. These clinics are primarily located at district-level government healthcare facilities. The market is projected to develop in this region due to the rising frequency of STDs002E.
The China market dominated the Asia Pacific Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $227.1 million by 2030. The Japan market is registering a CAGR of 8.5% during (2023-2030). Additionally, The India market would showcase a CAGR of 9.9% during (2023-2030).
Based on Product, the market is segmented into Assays & Kits, and Instruments & Analyzers. Based on End-user, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics, and Others. Based on Testing Type, the market is segmented into Lab Tests, and PoC Tests. Based on Technology, the market is segmented into Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, ZeptoMetrix LLC (Antylia Scientific), Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., Thermo Fisher Scientific, Inc., Bayer AG, Qiagen N.V. and Siemens AG.
Early Chlamydia and Gonorrhoeae detection becomes feasible by CT/NG testing, allowing rapid treatment and stopping the spread of diseases. As a result, communities see lower transmission rates, and individuals experience better health outcomes. The accuracy and specificity of CT/NG tests have also been improved due to developments in molecular diagnostics and genotyping techniques. These technologies make it possible to identify individual strains and patterns of medication resistance, enabling more precise treatment methods and improved infection control.
Personalized options for treatment are rendered accessible by incorporating genotyping and molecular diagnostics into CT/NG testing. It helps optimize treatment plans based on unique infection profiles, prevent antibiotic resistance, and enhance therapeutic outcomes. Additionally, the healthcare sector's integration of telemedicine and digital health platforms makes remote testing, consultations, and result distribution possible. In particular, for people in underprivileged areas, this removes geographic restrictions and improves accessibility to testing services. Professional people looking for testing services and telemedicine solutions in the market offer ease and privacy. Confidentiality is ensured with remote testing, removing obstacles and stigma connected to conventional in-person appointments.
According to a 2023 National Library of Medicine, publication named Sexually Transmitted Infections Among Key Populations in India: A Protocol for Systematic Review, between 0 to 3.9 percent of the general population in India has one of the four treatable STIs. However, subpopulations engaging in high-risk behavior are believed to have considerably greater STI prevalence than the general population. As a result, officials are taking more action to address the issues. The National AIDS Control Organization (NACO) has made STI prevention one of its primary goals in India for the past 20 years. Through its network of more than 1100 designated clinics, known as Suraksha Clinics, the NACO offers free sexual and reproductive health services based on syndromic case management through trained counselors, skilled paramedics, and experienced medical personnel. These clinics are primarily located at district-level government healthcare facilities. The market is projected to develop in this region due to the rising frequency of STDs002E.
The China market dominated the Asia Pacific Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $227.1 million by 2030. The Japan market is registering a CAGR of 8.5% during (2023-2030). Additionally, The India market would showcase a CAGR of 9.9% during (2023-2030).
Based on Product, the market is segmented into Assays & Kits, and Instruments & Analyzers. Based on End-user, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics, and Others. Based on Testing Type, the market is segmented into Lab Tests, and PoC Tests. Based on Technology, the market is segmented into Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, ZeptoMetrix LLC (Antylia Scientific), Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., Thermo Fisher Scientific, Inc., Bayer AG, Qiagen N.V. and Siemens AG.
Scope of the Study
By Product
- Assays & Kits
- Instruments & Analyzers
By End-user
- Diagnostic Laboratories
- Hospitals & Clinics
- Others
By Testing Type
- Lab Tests
- PoC Tests
By Technology
- Isothermal Nucleic Acid Amplification Technology
- Polymerase Chain Reaction
- Immunodiagnostics
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Becton, Dickinson and Company
- ZeptoMetrix LLC (Antylia Scientific)
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- Hologic, Inc.
- Thermo Fisher Scientific, Inc.
- Bayer AG
- Qiagen N.V.
- Siemens AG
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product
Chapter 5. Asia Pacific Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User
Chapter 6. Asia Pacific Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type
Chapter 7. Asia Pacific Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology
Chapter 8. Asia Pacific Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Becton, Dickinson and Company
- ZeptoMetrix LLC (Antylia Scientific)
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- Hologic, Inc.
- Thermo Fisher Scientific, Inc.
- Bayer AG
- Qiagen N.V.
- Siemens AG
Methodology
LOADING...
